Program

The 71st Annual Meeting of the Japanese Cancer Association − Towards a new era and liaison of cancer research and life science −

Program

The 71^st Annual Meeting of the Japanese Cancer Association
-Towards a new era and liaison of cancer research and life science-

Program at a Glance

Show Full Program
Collapse Program

Plenary Lecture

Plenary lecture 1

Wednesday, September 19, 1:00 PM

Chairperson:	Naoyuki Taniguchi, RIKEN
Speaker:	Kazuhiro Nagata, Kyoto Sangyo University Stress responses and cellular homeostasis

Collapse

Plenary lecture 2

Thursday, September 20, 1:00 PM

Chairperson:	Hiroshi Shiku, Mie University
Speaker:	James P. Allison, Memorial Sloan-Kettering Cancer Center Beyond Immune Checkpoint Blockade: Manipulation of T cell regulatory circuits in Cancer Therapy

Collapse

Special Program

How to promote the merits of cancer research in Japan

Thursday, September 20, 2:00PM

Chairpersons:	Ryuzo Ueda, Aichi Medical University
Chairpersons:	Tetsuo Noda, The Cancer Institute of JFCR
Speakers:	Morito Monden, The Cancer Control Promotion Council
	Tomomitsu Hotta, National Cancer Center
	Shinsuke Amano, Group Nexus Japan
	Yusuke Nakamura, scientist, The University of Chicago / The University of Tokyo
	Naoko Okamura, Ministry of Education, Culture, Sports, Science and Technology
	Hirotsugu Kimura, Ministry of Health, Labour and Welfare

Collapse

Panel Discussion
(JCA-Japanese Society of Clinical Oncology Joint Program)

Current Status and Future Prospects of Translational Research in Japan

Friday, September 21, 9:00AM

Chairpersons:	Kiyotaka Kuzushima, Aichi Cancer Center
	Yutaka Kohgo, Asahikawa Medical University
Speakers:	Kenichi Tamiya, Ministry of Health, Labour and Welfare
	Shinichi Kageyama, Mie University Academia-based activities of translational research
	Toshiyuki Sakai, Kyoto Prefectural University of Medicine The strategy from finding seeds to TR.
	Shiro Akinaga, Kyowa Hakko Kirin Co., Ltd. Status of Japan-initiated translational research: A view from a Japanese Pharmaceutical Company
	Koichi Fukino, Novartis Pharma K.K. Translational Research in Japan; from the view points of the global pharmaceutical company
	Nishiyama Masahiko, Saitama Medical University Translational Research Network in Asia as a Possible Approach to Future Development Study on Cancer Therapeutics

Collapse

JCA-AACR Joint Symposium

Advancement of cancer immunology and immunotherapy

Thursday, September 20, 9:00 AM

Chairpersons:	Yutaka Kawakami, Keio University
Chairpersons:	James P. Allison, Memorial Sloan Kettering Cancer Center
Speakers:	Toshihiko Torigoe, Sapporo Medical University Immunopathological properties of cancer stem cells and application to cancer immunotherapy
	Carl H.June, University of Pennsylvania CAR T cells for leukemia and more?
	Glenn Dranoff, Dana-Farber Cancer Institute Mechanisms of Protective Tumor Immunity
	Shinichi Hashimoto, Kanazawa University Genome-wide single cell transcriptome and methylome methods for improvement of cancer immunotherapy
	Yutaka Kawakami, Keio University Multiple immunosuppressive cascades induced by cancer cells and their control by signal inhibitors

Collapse

Core Symposium

1. Projection from basic biology to cancer research

Wednesday, September 19, 2:00 PM

Chairpersons:	Noriyuki Sato, Sapporo Medical University
	Stuart Calderwood, Beth Israel Deaconess Medical Center
Speakers:	Stuart Calderwood, Beth Israel Deaconess Medical Center Transcriptional Regulation of Molecular Chaperones in cell stress and cancer
	Kazutoshi Mori, Kyoto University The unfolded protein response and cancer
	Tohru Nakano, Osaka University DNA methylation in development and transformation
	Yoshinori Watanabe, The University of Tokyo Chromosomal instability in cancer cells is caused by shugoshin dysfunction
	Masanori Hatakeyama, The University of Tokyo Role of Helicobacter pylori CagA oncoprotein in gastric carcinogenesis

Collapse

2. New paradigm developed by next-generation sequencer

Thursday, September 20, 2:00 PM

Chairpersons:	Hiroyuki Aburatani, The University of Tokyo
	Tatsuhiro Shibata, National Cancer Center Research Institute
Speakers:	Hiroyuki Aburatani, RCAST, The University of Tokyo Genomics of cancer progression
	Mamoru Kato, Cold Spring Harbor Laboratory Evolutionary analysis of single-cell sequencing data to detect natural selection in tumor cells
	McDermott Ultan, Cancer Genome Project, Wellcome Trust Sanger The genomics of drug sensitivity in cancer.
	Tatsuhiro Shibata, National Cancer Center Research Institute Cancer transcriptome sequencing
	Seishi Ogawa, The University of Tokyo Hospital Cancer Board Novel pathway mutations in myelodysplasia as revealed by whole genome/exome sequencing
	Jeffrey S. Ross, Department of Pathology and Laboratory Medicine Albany Medical College Next-Generation Pathology: Deep DNA Sequencing and Targeted Therapy for Cancer

Collapse

3. Integration of developmental biology and cancer

Thursday, September 20, 9:00 AM

Chairpersons:	Tetsuo Noda, The Cancer Institute of JFCR
	Masahide Takahashi, Nagoya University
Speakers:	Masahide Takahashi, Nagoya University Roles of AKT substrate Girdin in cancer progression and angiogenesis
	Kwok Kin Wong, Dana Farber Cancer Institute Mouse Models of Lung Cancer Progression
	Makoto Mark Taketo, Kyoto University Metastasis suppressor gene AES/Aes is an endogenous Notch signaling inhibitor
	Akira Suzuki, Kyushu University Functional analysis of tumor suppressor genes Mob1A/1B
	Takuro Nakamura, The Cancer Institute of JFCR Oncogenic stimuli and tumor origin

Collapse

4. Scientific progress of human tumor immunology

Wednesday, September 19, 9:00 AM

Chairpersons:	Kohzoh Imai, The University of Tokyo
	Yusuke Nakamura, The University of Tokyo
Speakers:	Yusuke Nakamura, The University of Tokyo Development of therapeutic cancer peptide vaccine and construction of translational research network
	Yasuharu Nishimura, Kumamoto University Efficient induction of tumor immunity by the ideal TAA-derived peptides carrying both CTL and Th1 cell epitopes
	Kouji Matsushima, The University of Tokyo Alleviation of GVHD by anti-CD4 antibody preserving GVL/T effect in allo-HSCT
	Francesco M Marincola, National Institutes of Health Common signatures of rejection

Collapse

5. Molecular pathology of cancer stem cell/cancer initiating cell

Friday, September 21, 9:00 AM

Chairpersons:	Kohei Miyazono, The University of Tokyo
	Toshio Suda, Keio University
Speakers:	Kohei Miyazono, The University of Tokyo Regulation of cancer-initiating cell function by TGF-beta
	Koichi Akashi, Kyushu University Pathogenesis of Cancer Stem Cells in Human Hematological Malignancies
	Keiyo Takubo, Keio University Regulation of leukemia initiating cells in the hypoxic niche
	Daniel G. Tenen, Cancer Science Institute of Singapore, NUS Regulation of myeloid transcription factors and DNA methylation by noncoding RNAs

Collapse

International Sessions

1. Translational gastric cancer research

Wednesday, September 19, 9:00 AM

Chairpersons:	Masahiro Asaka, Hokkaido University
	Khay-Guan Yeoh, National University of Singapore
Speakers:	Toshikazu Ushijima, National Cancer Center Research Institute Bringing Epigenetic Field Defect into Cancer Risk Diagnosis and Prevention
	Li-Ling Lin, National Taiwan University Annexin A4, a gastric cancer marker, triggers a signaling cascade for cell proli feration
	Patrick Tan, Genome Institute of Singapore Dissecting Gastric Cancer Heterogeneity : Genomic Approaches and Clinical Impact
	Sun Young Rha, Yonsei Cancer Center, Yonsei University Strategic approach of new drug development in gastric cancer
	Mitsuru Kaise, Toranomon Hospital Advances in endoscopic diagnosis and treatment for gastric cancer
	Khay-Guan Yeoh, National University of Singapore Early detection of gastric cancer: Predicting high risk groups
	Mototsugu Kato, Hokkaido University Hospital Strategy for elimination of gastric cancer in Japan

Collapse

2. Perspective of molecular epidemiologic cohort in Asia

Wednesday, September 19, 9:00 AM

Chairpersons:	Keitaro Matsuo, Aichi Cancer Center Research Institute
	Daehee Kang, Seoul National University
Speakers:	Daehee Kang, Seoul National University Evolution of Cohort Studies in Asia
	Motoki Iwasaki, National Cancer Center Current status of molecular epidemiologic cohort study in National Cancer Center, Japan
	Kenji Wakai, Nagoya University Graduate School of Medicine The Japan Multi-institutional Collaborative Cohort (J-MICC) Study: its achievement and perspectives
	Hidemi Ito, Aichi Cancer Center Research Institute Potential of the Hospital based Epidemiologic Research Program at Aichi Cancer Center as a genome cohort study
	Woon-Puay Koh, National University of Singapore Gene-environment interactions and cancer risk: findings from The Singapore Chinese Health Study
	Minkyo Song, Seoul National University, College of Medicine Profiles of the Health Examinees Study using Biomarker in Korean Population: An Interim Report
	Fang-Hui Zhao, Cancer Institute/Hospital,Chinese Academy of Medical Sciences Effectiveness and Health Economic Analysis of Strategies on Cervical Cancer Screening and Early Diagnosis and Treatment

Collapse

3. Tumor angiogenesis

Friday, September 21, 2:00 PM

Chairpersons:	Kyoko Hida, Hokkaido University
	Gou Young Koh, Korea Advanced Institute Science and Technology (KAIST)
Speakers:	Gou Young Koh, Korea Advanced Institute Science and Technology (KAIST) Role of VEGF-A and Angiopoietins in Tumor Angiogenesis and Vessel Destabilization
	Yasufumi Sato, Tohoku University The role of vasohibin family in cancers
	Tetsuro Watabe, University of Tokyo Roles of signaling and transcriptional networks during TGF-beta-induced endothelial-to-mesenchymal transition (EndMT)
	Young-Guen Kwon, Yonsei University, Korea Promotion of vascular integrity resulted in normalization of tumor blood vessels
	Kyoko Hida, Hokkaido University Crosstalk between tumor endothelial cells and tumor cells.
	Nobuyuki Takakura, Osaka University Requirement for perivascular niche for maintenance of cancer stem cells

Collapse

4. Development of new anticancer drugs in Asia

Friday, September 21, 2:00 PM

Chairpersons:	Atsushi Ohtsu, National Cancer Center
	Hyun Cheol Chung, Yonsei University
Speakers:	Huei-Wen Chen, National Taiwan University Medical College Hinokitiol inhibits gefitinib-resistant lung adenocarcinoma cancer cell prolifer ation through G2/M arrest
	Toshihiko Doi, National Cancer Center Hospital East Development of new anticancer drugs in Asia: early clinical trials in c-MET/HGF signal inhibitors
	Hyun Cheol Chung, Yonsei University Early clinical trial of anti-angiogenesis agents for BAD determination
	Eng-Huat Tan, National Cancer Centre, Singapore Drug development in Lung Cancer in Asia
	Kenji Tamura, National Cancer Center Hospital Development of new anti-cancer drugs in the field of breast cancer in Asia
	Winnie Yeo, Chinese University of Hong Kong Epigenetic Therapy in Liver Cancer
	Takayuki Yoshino, National Cancer Center Hopital East Update on Promising New Agents for Unresectable Metastatic Colorectal Cancer
	Sumimasa Nagai, Pharmaceuticals and Medical Devices Agency The comparison of review process of drugs for hematological malignancies by the PMDA with the FDA

Collapse

5. Molecular targets for cancer therapy

Thursday, September 20, 2:00 PM

Chairpersons:	Hiroyuki Seimiya, JFCR Cancer Chemotherapy Center
	In-Hoo Kim, National Cancer Center
Speakers:	In-Hoo Kim, National Cancer Center Development and application of aptamer-antibody hybrid complex as an efficient targeting agent
	Hiroyuki Seimiya, JFCR Cancer Chemotherapy Center Targeting glioma stem cells by G-quadruplex ligands
	Siu Tim Cheung, The University of Hong Kong Genomic approach identified growth factor GEP and ABC transporters associated with HCC recurrence and chemoresistance
	Tomohiro Fujiwara, National Cancer Center Research Institute A Novel Therapeutic Strategy against Tumor-initiating Cells of Osteosarcoma: microRNA Inhibition with Current Treatment
	Yon Hui S. Kim, National Cancer Center, Korea Multi-layer integrative analysis of the whole transcriptome in Asian gastric cancer
	Seiji Yano, Cancer Research Institute, Kanazawa University Ligand-stimulated receptor activation as novel targets to overcome resistance to molecular targeted drugs in lung cancer
	Ryohei Katayama, MGH Cancer Center/Harvard Medical School Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers

Collapse

6. Inflammation and cancer

Thursday, September 20, 9:00 AM

Chairpersons:	Masanobu Oshima, Kanazawa University
	Young-Joon Surh, Seoul National University
Speakers:	Masanobu Oshima, Kanazawa University Inflammation and Cancer
	Hye-Kyung Na, Sungshin Women's University, Seoul, Korea 15-Hydroxyprostaglandin Dehydrogenase as a Novel Target for Chemoprevention of Inflammation-Associated Carcinogenesis
	Akira Kikuchi, Osaka University Wnt as a common mediater for inflammation and tumorigenesis
	Brendan J. Jenkins, Monash University Novel role for TLR2 promoting tumorigenesis independent of inflammation in gastric cancer
	Yoshiro Maru, Tokyo Women's Medical University An interface between metastasis and inflammation
	Junichiro Inoue, The University of Tokyo Critical roles of NF-kB activation in breast cancer development
	Young-Joon Surh, Seoul National University Modulation of Pro-inflammatory and Anti- inflammatory Signaling for Cancer Chemoprevention and Treatment

Collapse

7. Cancer nanomedicine

Thursday, September 20, 2:00 PM

Chairpersons:	Yasuhiro Matsumura, National Cancer Center Hospital East
	Wu-Chou Su, National Cheng Kung University
Speakers:	Tetsuya Hamaguchi, National Cancer Center Hospital Clinical studies of polymer micelles incorporating anticancer agents
	Wu-Chou Su, National Cheng Kung University The development of nanodevices engineered to suppress IL-6/Jak/Stat3 pathway to improve cancer treatment
	Hidetaka Akita, Hokkaido University Development of the nanoparticle for DNA vaccine based on the control of intracellular trafficking and signaling
	Maggie Lu, ITRI The nanomedicine approach for treating glioblastoma
	Yi-Yan Yang, Institute of Bioengineering and Nanotechnology, Singapore Micelles Self-Assembled from Polycarbonate-PEG Block Copolymers for Anticancer Drug Delivery
	Nobuhiro Nishiyama, The University of Tokyo Design of polymeric micelles for the targeting of intractable cancers.

Collapse

8. Cancer genome sequencing and how to interpret mutation data

Thursday, September 20, 9:00 AM

Chairpersons:	Hidewaki Nakagawa, Center for Genomic Medicine, RIKEN
	Jun Wang, Beijing Genomics Institute (BGI)
Speakers:	Akihiro Fujimoto, Center for Genomic Medicine, RIKEN Whole genome sequence and comprehensive data analysis of cancer genome
	Masashi Sanada, The University of Tokyo Novel pathway mutations in myelodysplasia revealed by high throughput sequencing technology
	Niranjan Nagarajan, Genome Institute of Singapore Landscape of Somatic Alterations and their Functional Consequences in Gastric Cancer
	Ren Shancheng, Shanghai Changhai Hospital RNA-seq analysis of Chinese prostate cancer identifies recurrent gene fusions, cancer-associated long noncoding RNAs
	Jun Wang, Beijing Genomics Institute (BGI) Genetic Analysis of three Cancers and Cancer Progression Using Single-Cell Sequencing

Collapse

9. Molecular imaging in cancer research and treatment

Wednesday, September 19, 2:00 PM

Chairpersons:	Masahiro Hiraoka, Kyoto University
	June-Key Chung, Seoul National University Hospital
Speakers:	June-Key Chung, Seoul National University Hospital Introduction of molecular imaging
	Arifudin Achmad, Gunma University A Preliminary Report on HER1-targeted PLGA-PEG Nanobubbles as an Intratumor-specific targeted Ultrasound Contrast Agent
	Keon Wook Kang, Seoul National University College of　Medicine in vivo Nano-Molecular Imaging of Cancer
	Hiroshi Harada, Kyoto University Cancer cells that acquire HIF-1 activity after radiotherapy cause local tumor recurrence; An optical imaging research
	Koichi Yasuda, Hokkaido University Graduate School of Medicine Hypoxia imaging and Radiation therapy

Collapse

10. Basic and clinical advances in cancer epigenetics research

Friday, September 21, 9:00 AM

Chairpersons:	Hiromu Suzuki, Sapporo Medical University
	Mingzhou Guo, Chinese PLA General Hospital
Speakers:	Keiko Shinjo, Aichi Cancer Center Research Institute Clinical implications of epigenetic markers in thoracic malignancies
	Joo Mi Yi, Dongnam Institute of Radiological & Medical Sciences (DIRAMS) Clinical Application of DNA Hypermethylome in Colon Cancer
	Hiromu Suzuki, Sapporo Medical University Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors
	Mingzhou Guo, Chinese PLA General Hospital Methylation of DACT2 Activated WNT Signaling Pathway in human Lung and GI Cancer
	Sung-Liang Yu, National Taiwan University DNA methylation involved in chemotherapeutic efficacy in lung cancer
	Katsuya Ohta, Osaka University Epigenetic Regulation Modulates Biological Behaviors of Colon Cancer Stem Cells

Collapse

11. Maintaining the integrity of genomic information by cell cycle checkpoints

Friday, September 21, 9:00 AM

Chairpersons:	Makoto Nakanishi, Nagoya City University
	Hyeseong Cho, Ajou University
Speakers:	Hyeseong Cho, Ajou University Mitotic Regulation of Rsf-1, a Subunit of Remodeling and Spacing Factor Complex
	Randy Poon, The Hong Kong University of Science and Technology Mitotic catastrophe: mechanisms and therapeutic potential
	Yoshikazu Johmura, Nagoya City University Senescent cells are tetraploid G1 cells generated by mitotic skipping
	Richard W. Wong, Kanazawa University The role of Nuclear Pore Proteins in coordination of cell cycle checkpoints during mitosis
	Junya Unno, Kyoto University Crosstalk signaling between checkpoint and the Fanconi anemia DNA repair pathway
	Akimitsu Konishi, Tokyo Medical and Dental University Checkpoint recovery from DNA damage
	Hong-Duk Youn, Seoul National University College of Medicine Cell cycle regulation by OGFOD1 in breast cancer cells

Collapse

12. Health care economics – The significance of UN-Summit NCDs political declaration in Asia (UICC International Session)

Wednesday, September 19, 2:00 PM

Chairpersons:	Hideyuki Akaza, University of Tokyo
	Jae Kyung Roh, Yonsei University
Speakers:	Norie Kawahara, The University of Tokyo Promoting perceptions of cancer as an integral part of the global health agenda
	Eun-Cheol Park, Yonsei University The economic burden of cancer in Korea
	Hajime Inoue, Chiba Prefecture Japan's role for controlling Non Communicable Diseases (NCDs) in Asia
	Keizo Takemi, Tokai University Political issue for realizing the declaration in the World
	Shinjiro Nozaki, The Global Health Workforce Alliance, WHO Geneva Health Workforce Crisis in the World
	Ludwig Kanzler, McKinsey & Company, Inc., Japan Innovative Financing of Cancer Care in Asia
	Masafumi Nogimori, Astellas Pharma Inc. Pharmaceutical industry’s contribution to the prevention and control of NCDs in accordance with the UN political declaration
	Pascal Rigaudy, sanofi-aventis K.K Oncology in Asian Countries: Clinical Development Challenges and Opportunities
	Jae Kyung Roh, Yonsei University Post Presentation Discussion; Health Care Economics - The Significance of UN-Summit NCDs Political Declaration in Asia

Collapse

Symposium

1. Recent development of chromosome and genome instability research

Wednesday, September 19, 9:00 AM

Chairpersons:	Fuyuki Ishikawa, Kyoto University
	Johji Inazawa, Tokyo Medical and Dental University
Speakers:	Fuyuki Ishikawa, Kyoto University Telomere dysfunctions and chromosome instability
	Noriko Hosoya, The University of Tokyo The role for a meiosis-specific protein in regulating DNA damage response and chromosome stability in cancer
	Johji Inazawa, Tokyo Medical and Dental University Mechanisms for complex rearrangements in human genome
	Yuichi Ishikawa, Cancer Institute of JFCR Chromosome and genome instability in lung and kidney tumors
	Hidewaki Nakagawa, RIKEN Center for Genomic Medicine Whole genome sequencing analysis of cancer

Collapse

2. Recent progress of non-coding RNA and cancer

Thursday, September 20, 2:00 PM

Chairpersons:	Hidetoshi Tahara, Hiroshima University
	Masatoshi Kitagawa, Hamamatsu University
Speakers:	Hidetoshi Tahara, Hiroshima University Micromanagement of cancer by senescence-associated micro RNA
	Hiroshi Suzuki, The University of Tokyo Complexity of microRNA biogenesis and inference of small RNA network through transcriptome analysis
	Gregory J. Goodall, Centre for Cancer Biology, SA Pathology UV-Crosslink Immunoprecipitation (HITS-CLIP) identifies regulatory networks targeted by the miR-200 family of microRNAs
	Ryouu Takahashi, National Cancer Center Research Institute Identification of microRNA-27b as a master regulator generating breast cancer stem cells
	Ken-ichi Kozaki, Tokyo Med. & Dent. Univ Methylation-based screening of tumor-suppressive microRNAs in cancer cells
	Tatsuya Ohhata, Hamamatsu University Recent progress of long non-coding RNA research
	Riki Kurokawa, Saitama Medical University Long noncoding RNA as an epigenetic regulatory factor

Collapse

3. Recent progress of epigenetics and cancer biology

Wednesday, September 19, 2:00 PM

Chairpersons:	Toshikazu Ushijima, National Cancer Center Research Institute
	Yutaka Kondo, Aichi Cancer Center Research Institute
Speakers:	Yutaka Kondo, Aichi Cancer Center Research Institute Epigenetic modifiers and non-coding RNA in plastic cancer stem-like cells and their therapeutic implications
	Satoshi Fujii, National Cancer Center Research Institute Histone adaptation of cancer cell
	Hideo Iba, The University of Tokyo A SWI/SNF complex catalytic subunit, Brm, as a key epigenetical regulator in cancer cells
	Atsushi Kaneda, The University of Tokyo Cancer epigenotypes and tumor development mechanisms
	Ajay Goel, Baylor University Medical Center Epigenetics of Colorectal Cancer
	Koji Hase, The University of Tokyo Intestinal microbiota shapes intestinal T cell balance via epigenetic modifications

Collapse

4. Molecular targeting to cancer stem cell/cancer initiating cell

Wednesday, September 19, 9:00 AM

Chairpersons:	Masaki Mori, Osaka University
	Toshihiko Torigoe, Sapporo Medical University
Speakers:	Yoshihiko Hirohashi, Sapporo Medical University Cancer Immunotherapy targeting to cancer stem cell/cancer initiating cell
	Naotsugu Haraguchi, Osaka University Cellular properties of cancer stem cells in gastroenterological cancer
	Hideyuki Saya, Keio University A novel therapeutic approach targeting the CD44 variant functions
	Takahiro Ochiya, National Cancer Center Research Institute Micromanaging cancer stem cells by targeting ribophorin II
	Noriko Gotoh, The University of Tokyo Growth factor receptor signaling controls breast cancer stem cells and their niche
	Shinji Tanaka, Tokyo Medical and Dental University Real-time imaging of pancreatic cancer stem cells to identify the selectively targeting therapy

Collapse

5. New aspect of cell cycle research and cancer

Wednesday, September 19, 2:00 PM

Chairpersons:	Keiichi Nakayama, Kyushu University
	Eiji Hara, The Cancer Institute of JFCR
Speakers:	Eiji Hara, The Cancer Institute of JFCR The roles and mechanisms regulating cellular senescence in cancer
	Keiichi Nakayama, Kyushu University Deciphering mechanism underlying G0 maintenance: Can we eradicate cancer stem cell?
	Makoto Nakanishi, Nagoya City University Inheritance of epigenetic information during DNA replication through a Uhrf1-Dnmt1 axis and replication machineries
	Tatsuo Fukagawa, National Institute of Genetics Kinetochore structure, which ensures for accurate chromosome segregation
	Philipp Kaldis, Institute of Molecular and Cell Biology (IMCB) Cdk1 is essential for cell division, suppression of DNA rereplication and tumor formation but not for liver regeneration
	Yoshinori Kagawa, Osaka University A novel cell cycle-associated RhoGAP, Celmobilin, regulates cancer cell motility and invasion in human.

Collapse

6. Signal transduction and cancer therapy

Friday, September 21, 9:00 AM

Chairpersons:	Hidenori Ichijo, The University of Tokyo
	Akinori Takaoka, Hokkaido University
Speakers:	Miki Kamiyama, The University of Tokyo ASK family-dependent stress signaling in tumor progression
	Mutsuhiro Takekawa, The University of Tokyo A novel role of the stress-responsive MAPK pathways in preventing centrosome amplification and its failure in cancer
	Nobuyuki Tanaka, Nippon Medical School Role of enhanced glycolysis in oncogenic transformation in culture cells and tumor development.
	Toru Kondo, Hokkaido University Analysis of signaling pathways that are involved in the maintenance of glioma-initiating cells.
	Masao Saito, University of Yamanashi Roles of TGF-β superfamily signals in EMT and cancer progression
	Tomohiko Tamura, Yokohama City University The transcription factor IRF8 in the pathogenesis and therapy of chronic myelogenous leukemia

Collapse

7. p53 family and cancer research

Wednesday, September 19, 9:00 AM

Chairpersons:	Takashi Tokino, Sapporo Medical University
	Akira Nakagawara, Chiba Cancer Center
Speakers:	Koichi Matsuda, The University of Tokyo Regulation of histone modification and chromatin structure by the p53-PADI4 pathway
	Masato Enari, National Cancer Center Research Institute p53 inactivation by anaplastic lymphoma kinase through tyrosine phosphorylation of p53
	Rieko Ohki, National Cancer Center Research Institute PH domain-only protein PHLDA3; a p53-regulated repressor of Akt and a novel tumor suppressor of endocrine tumors
	Yasushi Sasaki, Sapporo Medical University p53 family network and tumor suppression
	Kanaga Sabapathy, National Cancer Centre Singapore Expected and unexpected roles of the p53 family member, p73, in regulating carcinogenesis
	Yusuke Suenaga, Chiba Cancer Center Research Institute Functional roles of TAp63 and Myc in neural cancers

Collapse

8. Autophagy, proteostasis and cancer research

Wednesday, September 19, 2:00 PM

Chairpersons:	Hirofumi Arakawa, National Cancer Center Research Institute
	Shigetsugu Hatakeyama, Hokkaido University
Speakers:	Shigetsugu Hatakeyama, Hokkaido University TRIM proteins and cancers
	Tomohiko Ohta, Marianna University DNA replication and checkpoint regulated by HERC2 and BRCA1 E3 ubiquitin ligases
	Shigeomi Shimizu, Tokyo Medical and Dental University Alternative macroautophagy and cancer
	Shinji Saiki, Juntendo University Present status of development of cancer medicines targeting autophagy
	Alan Yueh-Luen Lee, National Health Research Institutes Overexpression of mitochondrial Lon protease contributes malignant tumor progression
	Jun Inoue, Tokyo Med. & Dent. Univ Gene aberration of autophagy-related genes in human cancers
	Hirofumi Arakawa, National Cancer Research Institute Mitochondrial quality control and cancer: Mieap, a p53-inducible protein, controls mitochondrial quality

Collapse

9. Cell competition and communication in cancer

Wednesday, September 19, 9:00 AM

Chairpersons:	Yasuyuki Fujita, Hokkaido University
	Takashi Kojima, Sapporo Medical University
Speakers:	Yasufumi Fujita, Hokkaido University Interactions between normal and transformed epithelial cells- A road to a novel type of cancer prevention and treatment
	Tatsushi Igaki, Kobe University Tumor growth regulation by cell competition
	Nobuyoshi Kosaka, National Cancer Center Research Institute Competitive interactions of cancer cells and normal cells via secretory microRNAs
	Yasufumi Omori, Akita University Recto-verso of connexin in cancer development and progression
	Makoto Asamoto, Nagoya City University Roloes of connexin expression in carcinogenesis and cell death

Collapse

10. Molecular pathophysiology of tumor microenvironment

Thursday, September 20, 2:00 PM

Chairpersons:	Motoharu Seiki, The University of Tokyo
	Atsushi Ochiai, National Cancer Center Hospital East
Speakers:	Genichiro Ishii, National Cancer Center Hospital East Pathobiological mechanism of tumor progression by cancer associated fibroblasts
	Akira Orimo, Juntendo University Carcinoma-associated fibroblasts educate incipient human mammary carcinoma cells to become invasive and metastatic
	Masahiro Sonoshita, Kyoto University Roles of Notch signaling in tumor microenvironment
	Naoya Fujita, The Cancer Institute of JFCR Involvement of platelet-tumor interaction in tumor cell survival and metastasis
	Yuichi Oike, Kumamoto University Role of Angiopoietin-like protein 2 in carcinogenesis and metastasis
	Takeharu Sakamoto, The University of Tokyo Mint3 promotes tumor malignancy in cancer and stromal cells
	Xueying Sun, Harbin Medical University Blocking Hypoxia-inducible pathways improves the efficacy of doxorubicin to treat hepatocellular carcinoma

Collapse

11. Molecular basis of tumor immunity enhancing

Thursday, September 20, 2:00 PM

Chairpersons:	Tsukasa Seya, Hokkaido University
	Yasuaki Tamura, Sapporo Medical University
Speakers:	Kensuke Miyake, The University of Tokyo Molecular mechanisms linking TLR7 distribution with TLR7-dependent IFNalpha production in plasmacytoid dendritic cells
	Tsukasa Seya, Hokkaido University A crucial RNA adjuvant for immunotherapy for cancer
	Tahiro Shin, Okaya City Hospital Aging-associated B7-DC+ B cells enhance anti-tumor immunity
	Yasuaki Tamura, Sapporo Medical University Heat shock proteins act as endogenous enhancers building a bridge between innate immunity and adaptive immunity
	Masato Tanaka, Tokyo University of Pharmacy and Life sciences The role of CD169 macrophages in anti-tumor immunity
	Hideki Ueno, Baylor Institute for Immunology Research Anti-tumor immunity induced by dendritic cell-based vaccine in cancer patients
	Hidetoshi Sumimoto, Teikyo University BRAF-MAPK signal inhibits chemokine production; Implication of BRAF-targeted therapy for immunotherapy in melanoma

Collapse

12. Perspective of new generation immunotherapy

Friday, September 21, 2:00 PM

Chairpersons:	Takashi Nishimura, Hokkaido University
	Kyogo Itoh, Kurume University
Speakers:	Ryuzo Ueda, Aichi Medical University Mogamulizumab is a promising new candidate of incorporated modulators for the cancer vaccine therapy
	Christoph H. Huber, TRON Institute, Mainz University Medical Centre, Germany Exploiting the Mutanome for Tumor Vaccination
	Tetsuro Sasada, Kurume University Personalized peptide vaccine: a novel treatment modality for advanced cancer
	Takashi Nishimura, Hokkaido University Development of an innovative cancer vaccine, helper/killer-hybrid epitope long peptide(H/K-HELP)
	Hisashi Wada, Osaka University NY-ESO-1 long peptide vaccine

Collapse

13. Live cell imaging and cancer research

Thursday, September 20, 9:00 AM

Chairpersons:	Yasuteru Urano, The University of Tokyo
	Takeshi Imamura, Ehime University
Speakers:	Shinae Kondoh, Tokyo Institute of Technology Functional real-time imaging of the tumor microenvironment
	Seiji Tobita, Gunma University Imaging of cellular oxygen levels and hypoxic tissues using iridium complex probes
	Hideo Higuchi, The University of Tokyo In vivo imaging of tumor and blood cells with high spatiotemporal precision
	Norihiro Kokudo, The University of Tokyo Liver cancer surgery guided by in vivo ICG fluorescence
	Hisataka Kobayashi, National Institutes of Health Molecular cancer imaging; Cutting edge of the theranostic technology
	Koji Okamoto, National Cancer Center Research Institute The functional screening method for metastasis-regulatory genes via combination of mouse models and fluorescent imaging

Collapse

14. Structural biology and cancer therapy

Thursday, September 20, 9:00 AM

Chairpersons:	Osamu Nureki, The University of Tokyo
	Katsumi Maenaka, Hokkaido University
Speakers:	Tatsuya Nishino, National Institute of Genetics Structural cell biology of chromosome segregation machinery
	Kouhei Tsumoto, The University of Tokyo Thermodynamic analysis of antibody-antigen interactions
	Shigeyuki Yokoyama, RIKEN Structural studies on cancer-related signaling and epigenetic proteins
	Masayuki Yamamoto, Tohoku University Molecular and Structural Basis of Keap1-Nrf2 System Function
	Kazumitsu Ueda, Kyoto University Crystal structure of a MDR1-type ABC protein
	Osamu Nureki, The University of Tokyo Structure of a dominant-negative helix-loop-helix transcriptional regulator suggests mechanisms of autoinhibition
	Katsumi Maenaka, Hokkaido University Structural basis for HLA recognition of killer cell Ig-like receptors

Collapse

15. Concurrent integration of pathology and cancer research

Friday, September 21, 2:00 PM

Chairpersons:	Shinya Tanaka, Hokkaido University
	Masashi Fukayama, The University of Tokyo
Speakers:	Yoshinori Murakami, The University of Tokyo Dual roles of a cell adhesion molecule, CADM1, in lung oncogenesis based on the molecular pathological analyses
	Makoto Sano, Nihon University Activation of Wnt/β-catenin signaling pathway in KrasG12D-induced pancreatic cancer development
	Etsuko Kiyokawa, Kanazawa Medical University Mechanisms for luminal cell filling detected by fluorescent live imaging
	Sug Hyung Lee, The Catholic University of Korea Apoptosis and autophagy: combination of pathological and genetical approach.
	Masahiko Kuroda, Tokyo Medical University Relationship between morphological structure and micro RNA signature during colon cancer development
	Shinya Tanaka, Hokkaido University Molecular and pathological analysis of malignant glioma: from tissues to therapeutic reagents
	Shunpei Ishikawa, The University of Tokyo Sequencing-based global analysis of cancer-microenvironment interactome

Collapse

16. Personalized cancer medicine and biomarker

Friday, September 21, 9:00 AM

Chairpersons:	Yasuhisa Shinomura, Sapporo Medical University
	Kazuto Nishio, Kinki University
Speakers:	Kiyoshi Yanagisawa, Nagoya University Proteomic identification of potential biomarkers of malignant pulmonary mesothelioma
	Hiroyuki Yamamoto, Sapporo Medical University Genetic alterations-based molecular diagnosis and personalized therapy of gastrointestinal cancer
	Takashi Kohno, National Cancer Center Research Institute The KIF5B-RET fusion gene: Individualized therapy of lung adenocarcinoma based on somatic genetic alterations
	Tetsuya Nakatsura, National Cancer Center Hospital East Potential of Cancer Immunotherapy for Personalized cancer medicine
	Kenji Yasuda, Tokyo Medical and Dental University Development of on-chip imaging flow cytometry technology for circulating tumor cell analysis
	Yasuhiro Koh, Shizuoka Cancer Center Research Institute Development of novel systems for the detection of circulating tumor cells in Japan
	Tomoko Yoshino, Tokyo University of Agriculture and Technology Development of microcavity array system for isolation and detection of circulating tumor cells

Collapse

17. Diabetes and cancer (JCA-Japan Diabetes Society Joint Symposium)

Friday, September 21, 2:00 PM

Chairpersons:	Masato Kasuga, National Center for Global Health and Medicine
	Hitoshi Nakagama, National Cancer Center Research Institute
Speakers:	Manami Inoue, Research Center for Cancer Prevention and Screening, National Cancer Center Diabetes and Cancer: Epidemiological Evidence
	Hiroshi Noto, National Center for Global Health and Medicine Cancer risk in diabetic patients treated with metformin
	Mei-Shu Lai, National Taiwan University Anti-diabetic drugs and cancer risk in type 2 diabetes mellitus patients
	Wataru Ogawa, Kobe University Insulin resistance and pathogenesis of cancer
	Michihiro Mutoh, National Cancer Center Research Institute Role of hypertriglyceridemia in diabetes-associated carcinogenesis
	Masahito Shimizu, Gifu University Targeting obesity-and diabetes-related metabolic abnormalities for chemoprevention of hepatocellular carcinoma
	Kohjiro Ueki, Tokyo University Possible mechanisms linking treatment for diabetes and cancer risk

Collapse

18. Challenging cancer research from international frontier

Friday, September 21, 9:00 AM

Chairpersons:	Toshimitsu Uede, Hokkaido University
	Kazuo Tajima, Aichi Cancer Center Research Institute
Speakers:	Lenan Shao, Department of Biomedical Engineering,Tohoku University Lymphatic drainage routes mapping in a n ovel experimental lymph metastasis model of mice
	Motomi Osato, National University of Singapore Runx family genes and tumorigenesis
	Shinichi Takayama, Boston Biomedical Research Institute Pathophysiological role of molecular chaperones in cancer and muscle disease
	Kwan-Hwa Chi, Shin Kong Hospital Modulation of Autophagy Pathway: Effective Combinations for Reversing Drug Resistance
	Naoto Hirano, University of Toronto The reality of "first-in-human" clinical trials in cancer research: Artificial APC-based adoptive cell therapy

Collapse

19. Radiation carcinogenesis

Thursday, September 20, 9:00 AM

Chairpersons:	Kiyoshi Miyagawa, The University of Tokyo
	Kenji Kamiya, Hiroshima University
Speakers:	Kotaro Ozasa, Radiation Effects Research Foundation Long-term radiation risk of cancer in the atomic-bomb survivors
	Kiyohiro Hamatani, Radiation Effects Research Foundation Characteristics of early molecular events in radiation-associated adult-onset papillary thyroid carcinogenesis
	Ignacia Tanaka, Institute for Environmental Sciences Neoplasia in Mice Exposed Chronically to Very Low Dose-Rates of Gamma Rays
	Ryo Kominami, Niigata University Radiation target cells in thymic lymphomas
	Peter Wushou Chang, Taipei Medical University Cancer risks from protracted low dose-rate ionizing radiation in a specific human population
	Sumitaka Hasegawa, Molecular Imaging Center, National Institute of Radiological Sciences Radiation-induced mouse thymic lymphomagenesis is accelerated by overexpression of H-ferritin

Collapse

Symposium on Specific Tumors

1. Topics of lung cancer

Wednesday, September 19, 9:00AM

Chairpersons:	Hirotoshi Akita, Hokkaido University
	Hiroyuki Mano, Jichi Medical University / The University of Tokyo
Speakers:	Ichiro Kinoshita, Hokkaido University Role of polycomb group protein EZH2 in lung cancer
	Tomoya Yamaguchi, Nagoya University TTF-1-induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma
	Manabu Soda, Jichi Medical University Targeting ALK-fusions in lung cancer
	Kengo Takeuchi, The Cancer Institute, Japanese Foundation for Cancer Research Novel fusion kinases in lung cancer
	S. Tiong Ong, Duke-NUS Graduate Medical School, Singapore A Novel BIM Polymorphism Linked to TKI Responses

Collapse

2. Topics of hematological malignancy

Wednesday, September 19, 2:00PM

Chairpersons:	Yoshihiro Matsuno, Hokkaido University Hospital
	Masao Seto, Aichi Cancer Center
Speakers:	Yoshikane Kikushige, Kyushu University Self-Renewing Hematopoietic Stem Cell Is the Primary Target in Pathogenesis of Chronic Lymphocytic Leukemia
	Momoko Nishikori, Kyoto University A murine model for elucidating the mechanism of lymphoma subtype determination
	Tadashi Yoshino, Okayama University Histological findings and molecular pathology of the lymphoma
	Kunihiro Tsukasaki, Nagasaki University Progress in the treatment of T-cell lymphoma
	Tomohiro Kinoshita, Aichi Cancer Center Hospital Recent progress in treatment of B-cell lymphoma

Collapse

3. Topics of gastrointestinal cancer

Thursday, September 20, 9:00AM

Chairpersons:	Koichi Hirata, Sapporo Medical University
	Yasuhiro Fujiwara, National Cancer Center Hospital
Speakers:	Yuichiro Doki, Osaka University Molecular biological characteristics of human esophageal cancers
	Tohru Niwa, National Cancer Center Research Institute Alterations of a histone modification is possibly involved in an epigenetic field for cancerization
	Akira Sawaki, Nagoya Daini Red Cross Hospital Epigenetic abnormalities associated with clinical variety of gastrointestinal stromal tumor
	Kazuto Nishio, Kinki University Biomarkers for prediction of GI cancer treatment
	Daiki Miki, Hiroshima University / RIKEN Genome-wide association study of hepatocellular carcinoma
	Koji Ueda, RIKEN Development of pancreatic cancer biomarkers by focused proteomic technologies
	Hitoshi Zembutsu, The University of Tokyo Genome-wide association study of pancreatic cancer and hematological toxicities in patients receiving gemcitabine.
	Rishu Takimoto, Sapporo Medical University Targeting Anticancer Drug Delivery to Pancreatic Cancer Cells Using　A Novel Nanoparticle Approach

Collapse

4. Topics of breast cancer

Thursday, September 20, 2:00PM

Chairpersons:	Yoshio Miki, Tokyo Medical and Dental University
	Shunsuke Haga, Nippon Medical School
Speakers:	Yoshio Miki, Tokyo Medical and Dental University Hereditary breast/ovarian cancer -New development of the molecular diagnosis and treatment-
	Seigo Nakamura, Showa University Hospital Current status and future perspectives for hereditary breast and ovarian cancer in Japan
	Hisataka Sabe, Hokkaido University RTKs-GEP100-Arf6-AMAP1 pathway mediates cancerous EMT in response to mutant p53 and TGFbeta1 signaling
	Shigehira Saji, Kyoto University Current treatment strategy to advanced or metastatic breast cancer
	Toyomasa Katagiri, The University of Tokushima New insight into developing treatment strategies for breast cancer
	Yutaka Tokuda, Tokai University Molecular-targeted therapy for breast cancer

Collapse

5. Molecular pathobiology of urologic neoplasm

Friday, September 21, 9:00AM

Chairpersons:	Taiji Tsukamoto, Sapporo Medical University
	Taizo Shiraishi, Mie University
Speakers:	Hiroshi Kitamura, Sapporo Medical University Biomarkers for prognosis and treatment selection in kidney and bladder cancer patients
	Yoji Nagashima Yokohama City University Pathology of renal neoplasms toward the era of molecular target therapy.
	Keiji Shimada, Nara Medical University Molecular biological and pathological factors for urothelial carcinoma progression
	Akira Yokomizo, Kyushu University The significance of clinicopathological factors associated with prognosis and therapeutic modalities in prostate cancer
	Yoshifumi Hirokawa, Mie University Effects of TGFb1 treated prostate cancer cell on tumor microenvironment and pathological examination of prostate cancer

Collapse

6. Topics of bone and soft part sarcoma

Friday, September 21, 2:00PM

Chairpersons:	Takuro Wada, Sapporo Medical University
	Yoshinao Oda, Kyushu University
Speakers:	Masanori Hisaoka University of Occupational and Environmental Health Molecular Pathology and Genetics in Soft Tissue Sarcomas
	Miwa Tanaka, The Cancer Institute, Japanese Foundation for Cancer Research Tumorigenic mechanisms of gene fusion-related sarcoma: study using animal models
	Yoshinao Oda, Kyushu University Investigation of the molecular target in soft tissue sarcoma
	Junya Toguchida, Kyoto University Application of stem cell research for the investigation of sarcoma pathology
	Akira Kawai, National Cancer Center Hospital Molecular markers of bone and soft tissue sarcomas revealed by proteomics
	Tomohide Tsukahara, Sapporo Medical University Peptide vaccination therapy for patients with bone and soft tissue sarcoma

Collapse

Lecture Symposium for Oncology Pharmacists

Wednesday, September 19, 2:00PM

Chairpersons:	Atsushi Miyamoto, Sapporo Medical University Hospital
	Toshihiro Hama, The Cancer Institute Hospital of JFCR
Speakers:	Katsuyuki Nakamura, Sapporo Medical University Hospital Contribution for safe and high quality cancer chemotherapy
	Maki Nemoto, The Cancer Institute Hospital Total management for cancer therapy by the Oncology Pharmacy Specialist
	Hisanaga Nomura, Kyorin Univeristy Hospital Finding solution to clinical question: Tips and Tools for Oncology Pharmacists.
	Yuki Kumihashi, Tokushima Red Cross Hospital Management of adverse reactions with regional community for cancer patients
	Makio Imamura, Kurashiki Medical Center A Challenge for Training Next-Generation Oncology Pharmacy Specialists.

Collapse